Goal of making treatment available to ALS patients at an early stage
First written in FY2023-Q3. 7 of 12 entries say "Restated". Latest entry: 2026-08-19.
No other company in this theme has enough history to compare yet.
- 2026-08-19AdvancedEarnings presentation
「Late 2020s Start of sales* (target)」
The company set a target timeline of the late 2020s for the start of sales of the ALS treatment. - FY2026-H1RestatedAnnual report
「For the ALS development pipeline, in Japan we are proceeding with preparations with Alfresa Pharma Corporation for the confirmatory clinical trial (Phase III trial) in order to deliver the treatment to patients as soon as possible.」
The company continues to target early delivery of the ALS treatment in Japan and to prepare for a Phase III trial with Alfresa Pharma Corporation. - FY2025AdvancedAnnual report
「Going forward, primarily Alfresa Pharma Corporation, the licensee, will continue discussions with the Pharmaceuticals and Medical Devices Agency (PMDA) and other relevant authorities while advancing preparations for the Phase III trial, which will evaluate safety and efficacy in a large number of patients, with a view to launching the product in the latter half of the 2020s.」
Regarding the ALS treatment, Alfresa Pharma Corporation has completed the Phase I clinical trial of KA-2301 and continues preparations for the Phase III trial. - FY2025-H1RestatedAnnual report
「In the iPS drug discovery business, we are researching 6 development pipelines. For the ALS pipeline, we are proceeding with preparations with Alfresa Pharma Corporation for the confirmatory clinical trial (Phase III trial) in order to deliver the treatment to patients as soon as possible.」
The company continues to target early delivery of the ALS treatment to patients and to prepare for the Phase III trial with Alfresa Pharma Corporation. - FY2024RestatedAnnual report
「In the iPS drug discovery business, we are researching 6 development pipelines. For the ALS pipeline, we are proceeding with preparations with Alfresa Pharma Corporation for the confirmatory clinical trial (Phase III trial) in order to deliver the treatment to patients as soon as possible.」
The company continues to target delivery of the ALS treatment to patients as soon as possible and to prepare for the Phase III trial. - FY2024-H1RestatedAnnual report
「In the iPS drug discovery business, we are researching 6 development pipelines. For the ALS pipeline, we are proceeding with preparations with Alfresa Pharma Corporation for the confirmatory clinical trial (Phase III trial) in order to deliver the treatment to patients as soon as possible.」
The company continues to target delivery of the ALS treatment to patients as soon as possible and to prepare for a Phase III trial with Alfresa Pharma Corporation. - FY2024-Q1RestatedAnnual report
「In the iPS drug discovery business, we are researching 6 development pipelines. For the ALS pipeline, we are proceeding with preparations with Alfresa Pharma Corporation for the confirmatory clinical trial (Phase III trial) in order to deliver the treatment to patients as soon as possible.」
The company continues to target delivery of the ALS treatment to patients as soon as possible and to prepare for a Phase III trial with Alfresa Pharma Corporation. - FY2023RestatedAnnual report
「Going forward, primarily Alfresa Pharma Corporation, the licensee, will continue discussions with the Pharmaceuticals and Medical Devices Agency (PMDA) and other relevant authorities while advancing preparations for the Phase III trial, with a view to launching the product in the latter half of the 2020s.」
The company continues to target early delivery of the ALS treatment to patients and describes preparations for a Phase III trial aimed at a launch in the latter half of the 2020s. - FY2023-Q3First statedAnnual report
「To deliver the treatment to patients as soon as possible, we will continue preparations with Alfresa Pharma Corporation for the confirmatory clinical trial (Phase III trial).」
The company has set early delivery to patients as its objective, with joint preparations with Alfresa Pharma Corporation as the specific means of achieving it.